US 12,668,795 B2 · Inhibitor of miR-129 and uses thereof

Abstract

The present invention relates to an inhibitor of miR-129, relative compounds and pharmaceutical compositions for use in the treatment and/or prevention of amyotrophic lateral sclerosis and Alzheimer's disease. The invention also relates to a method for the diagnosis and/or prognosis of Alzheimer's disease in a subject or to identify a subject at risk to develop amyotrophic lateral sclerosis or Alzheimer's disease and to a method for the measuring the efficacy of a therapy for amyotrophic lateral sclerosis or for Alzheimer's disease and relative kits.

Claims5

Dependent claims

A method for treating amyotrophic lateral sclerosis comprising administering a morpholino antisense oligonucleotide inhibitor of miR-129 to a subject diagnosed with amyotrophic lateral sclerosis, wherein said morpholino antisense oligonucleotide inhibitor of miR-129 comprises the sequence of SEQ ID NO:

Dependencies are inferred from the claim text.

Facts

Application

17/598,627Filed 26 Mar 2020

Priority

IT 10201900000457127 Mar 2019

Published

US 2022/0162611 A126 May 2022

Granted

30 Jun 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

C12N 15/113
DNA or RNA fragments; Modified forms thereof ; Non-coding nucleic acids having a biological activity: non-coding nucleic acids modulating the…
C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
C12N 2310/113
Antisense: targeting other non-coding nucleic acids, e.g. antagomirs
C12N 2310/3233
Modified ring structure: morpholino-type ring

Inhibitor of miR-129 and uses thereof

Life of this patent

Inhibitor of miR-129 and uses thereof

Life of this patent

Abstract

Claims5